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The last 2 years has seen an exponential rise in the amount of research funding made available 
for the development of rapid diagnostic devices for infectious agents of medical importance. 
This review reports on several such projects. These highlight the development of fully automated 
devices for rapid diagnostics, ranging from fully automated real-time PCR-based detection 
methods to fully automated PCR- and array-based machines for the detection and typing of 
influenza. This review will also highlight the importance of refocusing work on classical 
immunoassay techniques, showing how biosensor-based immunoassays can greatly enhance 
existing assays and at a much reduced cost to molecular-based methods. 
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Importance of rapid diagnosis of 
infectious disease 
Infectious disease represents the greatest risk 
to global human health. This can range from 
classical infectious diseases, such as T B , chol-
era, dysentery and typhoid, annual epidemics, 
such as norovirus, influenza and seasonal colds, 
emerging infectious diseases, such as avian influ-
enza and hemorrhagic fevers, through to global 
pandemics, such as H I V and the current newly 
emerged H I N l v outbreak (commonly referred 
to as swine flu). In the U K alone, infectious 
diseases account for 10% of all deaths recorded 
annually and are responsible for a third of all 
general practitioner consultations. The projected 
total cost for treatment of infectious diseases in 
the U K is approximately £6 billion per annum. 
In addition, public perception and awareness 
of infectious diseases has increased in recent 
years owing to increased coverage in the media 
of high-profile outbreaks of infectious diseases. 
Particular attention has been paid to cases of the 
human H5N1 highly pathogenic avian influenza 
infection and to the introduction of the virus 
into U K wild bird and poultry flocks. Public 
perception has also increased dramatically with 
regards to healthcare-associated infections, in 
particular methicillin-resistant Staphylococcus 
aureus (MRSA) and Clostridium difficile infec-
tions, and fatal outbreaks in hospitals. According 
to official figures on the Health Protection 
Agency website [ioi], there were 3210 cases of 
M R S A bacteremia reported in the U K in 2008 
with 1652 deaths, and an astonishing 81,412 
reported cases of C. difficile infection, with 
8324 deaths (fatality figures are from Office for 
National Statistics data, where the organism was 
named on death certificates [101]). 
Despite the obvious burden to human health 
and economic wealth presented by infectious 
diseases, the approach taken to diagnosis and 
effective treatment of these is firmly entrenched 
in classical microbiology of the early- and mid-
20th Century. Diagnosis for almost all infectious 
diseases caused by bacteria is still based on clas-
sical microscopic- and culture-based method-
ology. By adopting a culture-based program of 
infectious disease diagnosis, laboratories can 
perform tests on hundreds, i f not, thousands of 
samples per day using very cheap culture media 
and techniques able to be employed by semi-
skilled workers. It also provides clinical micro-
biologists with isolated bacterial cultures, which 
can be further characterized if necessary, such as 
antibiotic-resistance profiles or epidemiological 
testing in the event of an outbreak situation. 
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Classical diagnostics for infectious diseases 
To alleviate the burden of infectious diseases, diagnostic tests 
have been developed to identify pathogenic agents. This speeds 
up the appropriate treatment of patients and allows specific 
targeted drugs to be used, slowing the spread of infection to 
others [i]. The types of methods used include microscopy, cul-
ture, antigen detection and immunoserology [2]. The technique 
commonly used in clinical settings is culture on selective and 
chromogenic agars. In the last decade, many chromogenic agars 
have been developed to aid the rapid identification of bacte-
rial pathogens in several disease states, for example urinary 
tract infections (UTIs) and bacteremia [3-5]. Agars have been 
developed for specific pathogens, such as acrylonitrile-buta-
diene-styrene medium for Salmonella. [&), Candida diagnostic 
agar for Candida [7] and S. aureus ID agar or CHROMagar 
M R S A for MRSA [s-io]. Media used for potentially mixed 
pathogenic samples, such as those from U T I cases, include 
UriSelect3, Rainbow® Agar U T I medium and chromogenic 
U T I medium [3]. 
Microscopy and culture are also complemented in most clini-
cal diagnostic laboratories, with techniques such as antigen 
detection and serology (FIGURE I). These methods could be con-
sidered the forerunners of rapid diagnostics, as they principally 
remove the need for time-consuming, culture-based methods 
to direct detection of the infectious agent, or a response against 
that infectious agent. Both methods are antibody-based and are 
principally run on the basis of ELISA or immunofluorescent 
antigen testing. While both techniques speed up detection and 
diagnosis, there are numerous inherent problems with these 
techniques, as highlighted in BOX I. Despite this, commercial 
antigen detection and serology assays represent a huge mar-
ket and are commonly used for the diagnosis of HIV, influ-
enza, chlamydia and numerous other virus infections. Their 
use for diagnosis of viral infections has been particularly well 
employed by clinical laboratories, with the ELVIS technology 
a notable success for herpes simplex virus detection, which uses 
genetically modified cells that express the bacterial enzyme 
(3-galactosidase in the presence of the virus, which is easily 
detected histochemically [n]. The use of rapid diagnostics is 
perfect for such cases as culture and isolation of viruses, but it 
is extremely time consuming and cumbersome, relying on cul-
tured eukaryotic cells or embryonated eggs, with culture often 
taking as long as 7—14 days. Similarly, obligate intracellular 
organisms, such as Chlamydia, are much simpler to diagnose 
using antigen-detection tests, as opposed to intracellular cul-
ture of samples. In addition, many of these tests are now fully 
automated in clinical laboratories through the use of systems 
such as the Axsym® machine (Abbot Diagnostics). 
As the employment of serological and antigen-detection 
tests has increased for infectious organisms that are difficult 
to culture, the need for rapidity in diagnosing bacterial infec-
tions has also gathered pace. Many clinical laboratories now 
use automated systems such as the B A C T E C ™ system for 
bacterial blood cultures and Mycobacterium detection (Becton 
Dickinson). This works using barcode-labeled culture tubes 
that are inoculated and incubated. The incubator contains a 
light-emitting diode, and a scanner detects color changes in the 
inoculation vials as a result of C 0 2 production by bacterial res-
piration, producing an audible alarm to alert the microbiologist 
to the presence of bacteria in what should be a sterile sample. 
Drawbacks 
Al l diagnostic techniques have their shortcomings. A summary 
of the main challenges faced by traditional infectious disease 
diagnostic methods is presented in Box l . Culture-based diag-
nostic methods suffer particularly from the time taken to obtain 
a definitive result. Culture requires time to allow the bacteria 
of interest to grow, which is generally 24-72 h. Only after this 
time can the result be seen and this represents a huge delay to 
the treatment of patients. Ledeboer et al. investigated making 
the detection of Enterococcus spp. as rapid as possible using agar, 
but the fastest they were able to make their culture-based assay 
was 24 h [4]. If an organism has fastidious growing require-
ments, or is just slow growing, the diagnostic time is lengthened 
further. Culture methods also only account for those organisms 
that can be grown in the laboratory — those that cannot go 
unrecognized by these techniques. 
Apart from being time consuming, culture techniques are 
laboratory bound owing to the amount of equipment and 
reagents required to run them. This means that samples must 
be shipped to a laboratory before they can be analyzed. If col-
lected in a hospital, this is not such a problem, as samples can 
be analyzed in-house in hospital laboratories. However, this is 
not the case with samples collected outside of hospitals. During 
transport, samples may deteriorate or change from the state in 
which they were first collected owing to changes in temperature 
and aerobic status - such changes can have profound effects on 
the bacterial populations in the samples; thus, i f a microbiologi-
cal test is intended, it is important to store the samples carefully 
during transport. Disregarding changes in the sample itself, 
transport time lengthens the diagnostic procedure. Culture also 
requires a considerable amount of manual labor time preparing 
media, inoculating and attending to incubating cultures. 
Impact of molecular biology on diagnostics 
More advanced methods are now being used to supplement 
classical diagnostics utilizing nucleic acid probes specific for 
pathogens of interest, most notably in the diagnosis of blood 
culture samples using peptide nucleic acid FISH. This utilizes 
a fluorescent peptide nucleic acid that hybridizes to ribosomal 
R N A of septicemia pathogens and gives a positive identifica-
tion for sepsis diagnosis [12]. The technique targets the 16s 
R N A region of bacterial chromosomes, which are unique to 
each species and act as a fingerprint for bacteria. By designing 
a fluorescent probe that is complementary to this sequence, it is 
possible to detect bacteria at the molecular level by simply lysing 
cells in a sample in situ and adding the probe, then visualizing 
for fluorescence. This is very quick but also has drawbacks with 
regards to specificity, for example distinguishing M R S A from 
methicillin-sensitive S. aureus (MSSA). 
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initial microscopy performed 
if clinically important 
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or intracellular pathogen suspected 
Sample applied to culture medium 
and incubated for the required time 
(24-72 \ 
Figure 1. Processes involved in classical diagnosis of infectious disease, from receipt of sample through to confirmation 
of result. 
The ability to amplify nucleic acids has opened the door to 
identifying pathogens by detecting the presence of their D N A in 
samples without the need to culture first to increase their num-
bers [2,13]. D N A detection can be achieved much more rapidly 
than culturing, thus diagnoses may be available in just a few-
hours. It avoids the problem posed by fastidious or nonculturable 
organisms and can be used to identify organisms more specifi-
cally than culture, since primers and probes may be designed 
for specific organisms (FIGURE 2). Amplification-based nucleic acid 
methods may be identified into three groups: target nucleic acid 
amplification, probe amplification or signal amplification [14]. 
Polymerase chain reaction, strand-displacement amplifica-
tion and isothermal R N A self-sustaining sequence replication 
are examples of target amplification. The latter is the basis for 
nucleic acid sequence-based amplification and transcription-
mediated amplification. P C R consists of a number of tempera-
ture cycles that include a denaturing, annealing and sometimes 
an extension temperature [15]. The D N A template of choice 
(from a pathogenic bacterium for diagnostic purposes) is sub-
jected to this cycle of temperature changes in the presence 
of a polymerase enzyme, free nucleotides, primer nucleotide 
sequences and chemical buffers. This enables the polymerase 
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Box 1. Limitations of traditional 
diagnostic techniques. 
Microscopy 
• Poor sensitivity 
• Invasive 
• False-positives obtained 
Culture 
• Time consuming 
• Slow-growing organisms 
• Uncultured/fastidious organisms 
• Biohazard 
Antigen detection 
• False-positives occur 
• Long-term antigen shedding 
• Narrow detection window 
Serology 
• Negative in immune-compromised patients 
• Complex interpretation 
• Poor correlation with disease 
• High background titers 
• Crossreactivity 
to create additional complimentary strands of D N A once the 
original strands have denatured and primer fragments have 
annealed. The product of the PCR, the D N A fragment selected 
by the primer placement, doubles during every cycle, thus 
increasing the amount of the chosen nucleic acid dramatic-
ally. The transcription-mediated amplification and nucleic acid 
sequence-based amplification reactions amplify R N A by the 
action of three enzymes: reverse transcriptase, RNase and R N A 
polymerase. First, c D N A i s synthesized by special primers, one 
end of which is target specific and the other end is promoter 
R N A polymerase. Reverse transcriptase synthesizes RNA— 
D N A hybrid, and the RNase digests the R N A component of 
this. The reverse transcriptase then synthesizes dsDNA, and 
finally, the R N A polymerase makes numerous R N A copies. 
The ligase chain reaction (LCR) in the gapped L C R format is 
a combination of target- and probe-amplification processes, and 
the QB replicase amplification is an example of probe amplifica-
tion [15]. In L C R , dsDNA is denatured by heating, and primers 
anneal to the single strands. Then, the D N A ligase joins the 
primers, and the product is again released by heating. This 
product goes on to become the template for further ligations. 
Gapped L C R simply adds a D N A polymerase step to fill a 
gap of a few bases left between the primers, before the ligase 
may join them. In QB replicase amplification, the R N A probe 
anneals to the target and the hybrids are captured; the probe 
is then removed and amplified by the QB replicase. However, 
problems have been seen regarding the separation of hybridized 
and nonhybridized probe. 
A l l of the aforementioned amplification reactions have been 
improved by the advent o f real-time PCR technology. This 
has the benefit over conventional amplification reactions in 
that it does not require electrophoresis of products after the 
amplification reaction, minimizing postmethod contamination, 
but rather uses fiuorescently labeled nucleotides (Sybr technol-
ogy) or a fiuorescently labeled probe complementary to the 
target sequence, which anneals between the two primers used 
in the amplification reaction (TaqMan technology; Roche). 
TaqMan works by addition of a fluorophore and a quencher 
molecule to the probe. In the absence of complementary target 
molecules, the quencher inhibits the emission of light by the 
fluorophore. If bound to target D N A , the molecules are sepa-
rated by distance, and fluorescence is emitted. This is detected 
by a sensor that scans the reaction after each P C R cycle, hence 
the real-time detection of target molecules. Real-time P C R is 
a much faster process, and target molecules can be detected in 
as little as 30 min i f abundant in a test sample [16]. The two 
main benefits of this real-time scanning process are that a posi-
tive sample can be detected during the P C R assay, rather than 
having to wait for the cycling and then a further electrophore-
sis step, and that as P C R and incorporation of fluorescence is 
a logarithmic process, one can actually quantify the amount 
of target in a sample by using a calibration curve composed 
via positive-control samples containing known amounts of the 
target. This creates the power of quantifiable culture-based 
diagnosis using the rapidity of molecular-based tests. 
In addition, microrray technology could also be of use in 
diagnostics for infectious agents [17]. This involves glass slides 
that contain ssDNA molecules complementary to pathogen-
specific sequences. By amplifying the microbial D N A or R N A 
present in a sample, it is potentially possible to identify all 
microbes present in a clinical sample on one test assay. The 
amplification incorporates fluorescently labeled nucleotides into 
the amplified product, and hybridization is assessed using laser 
excitation and fluorescence emission readings. 
There are an astonishing number of peer-reviewed publica-
tions on the development and implementation of PCR-based 
detection assays for infectious agents, far too many to cover in 
a concise review; however, a fine example of the process behind 
the rationale and design of such assays is the development of a 
PCR assay for MRSA specifically, rather than all S. aureus strains. 
Methicillin resistance is conferred by a penicillin-binding protein 
called penicillin-binding protein 2a (PBP2a), which is coded for 
by the mecA gene [is]. A P C R assay was designed to detect the 
presence of this gene [19]; however, this assay also amplified other 
Staphylococcus species that were coagulase-negative in samples [20], 
creating a false positive for MRSA, and thus different assays were 
designed to be more specific. Reischl et al. used a duplex assay that 
combined primers for the mecA gene and primers for a S. aureus-
specific marker gene, such as nuc or sa442 [20]. However, this 
approach also led to false M R S A positives by picking up MSSA 
and coagulase-negative methicillin-resistant Staphylococci pres-
ent in the same sample. A more refined, tandem-target approach 
was also used by "Warren et al., whose assay targeted a sequence 
from the mobile genetic element that holds the mecA gene, 
SCCmec, and a sequence from the orfX region, a conserved open 
reading frame in which the SCCmec can be integrated into the 
genome and is uniquely found in M R S A [21]. Francois et al. used 
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a triplex assay to identify between S. aureus 
and Staphylococcus epidermidis [22]. Their 
assay included primers for mecA and femA 
specific for S. aureus znifamA specific 
for S epidermidis. 
Potential problems in developing 
molecular detection methods 
Molecular procedures have the risk 
of showing false-positive or -negative 
results [13]. False-positive results are pri-
marily due to contamination of the reac-
tion mixture from other samples and 
products of previous amplifications. 
Contamination during pipetting due to 
aerosols is also possible, since nucleic acid 
amplification is very sensitive and will pick 
up on tiny amounts of a contaminant. To 
combat the problem of contamination, 
urasik/V-glycosylase can be added to the 
reaction mix [23]; however, this does not 
remove the necessity for good laboratory 
practice when preparing molecular assays. 
The use of automated nucleic acid extrac-
tion and amplification techniques may also 
reduce contamination. 
False-negative results could be caused 
by a poorly designed assay that does not 
detect the target sensitively enough or 
only detects it when the target is present 
in high quantities. In such cases, the assay 
should be redesigned or a more effective target should be chosen 
for that pathogen. By their nature, molecular assays only use 
small amounts of a sample, considerably smaller than in culture 
techniques. Therefore, i f the pathogen for detection is present 
in low numbers in the first place, it is more likely to be missed 
when only a very small amounts of the subsample of the original 
sample is used. In this case, replicate assays may help to alleviate 
the problem, although they will add time and cost to the overall 
diagnostic process, so it would not be favored in a clinical set-
ting. Another cause of false negatives in clinical samples is the 
presence of inhibitors of nucleic acid amplification in the samples. 
Clinical samples are likely to consist of blood or feces, both of 
which contain substances that inhibit DNA-amplification reac-
tions [24,25]. TABLE 1 gives a list of inhibitory substances in clinical 
samples with their method of inhibition, if known. The com-
pounds are inhibitory because they interact with one or more of 
the reagents within the reaction mixtures. Anticoagulants, added 
to the samples to make them more suitable for some analyses, che-
late Mg2 + ions added to the reaction in the form of MgCl 2 , which 
reduces polymerase effectiveness [26]. Sodium polyanetholesulfo-
nate is added to blood cultures for its anticoagulant properties, 
and it is particularly difficult to remove when extracting D N A 
since it is a very similar molecule to D N A , sharing many of the 
same properties [27]. Morata et al. also found that incorporating 
Sample placed in automated 
diagnostic device - diagnostic 
process started (30 min-
Nucleic acide used in 
diagnostic process 
ommonly PCR, 1-2 
Figure 2. Molecular diagnostic process can, in theory, greatly simplify and speed 
up the process of diagnosis of infectious disease. 
more washing steps into their D N A extraction protocol removed 
inhibitors to allow successful PCR, although it also meant that 
the final yield of D N A was much lower [28]. Compounds within 
the blood itself also act as inhibitors, including hemoglobin, lac-
toferrin, heme and IgG [29,30]. The D N A extracted from fecal 
samples also shows amplification inhibition if not purified prior 
to use. There are numerous commercial kits available to extract 
D N A from feces; some that have been specifically designed for 
stool samples include the QIAamp® D N A stool minikit (Qiagen, 
Germany), the MagneSil™ KF Genomic System (Promega) and 
the MagaZorb® D N A M i n i Prep kit (Promega). Although these 
kits yield D N A that gives positive results for amplification, they 
do not perform as effectively with fecal samples when compared 
with extractions from samples of pure bacterial culture [31-33]. 
One other key challenge for molecular-based diagnostics is 
the standardization of assays between laboratories. There are an 
extremely limited number of commercially standardized molecu-
lar assays available, compared with the enormous number of ' in-
house' real-time PCR assays reported in the scientific literature 
each month. This creates problems in that diagnostic laboratories 
may be using different assays with differing degrees of sensitivity 
and specificity. Indeed, it has been shown that the use of differ-
ent in-house real-time P C R tests can impair direct comparison of 
diagnostics between laboratories [34], One key way of subverting 
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Table 1. Compounds found in clinical samples that inhibit nucleic acid 
amplification and their modes of action. 
m&& 
Blood Hemoglobin 
Lactoferrin 
Releases iron ions 
Releases iron ions 
Interacts with nucleic acids 
Feces 
Heme 
Leukocyte DNA 
Anticoagulant: EDTA 
Anticoagulant: heparin 
Sodium polyanetholesulfonate 
Immunoglobulin G 
Bile salts 
Bilirubin 
Urobilinogen 
Polysaccharides 
Heavy metals 
Urea 
Chelates Mg2+ 
Chelates Mg2+ 
Chelates Mg2+ 
Interacts with target DNA 
Chelates Mg2+ 
Chelating agent 
Chelating agent 
Urine 
these problems is by engaging diagnostic laboratories employing 
molecular-based diagnostics in well-defined and robust quality-
control programs [34]. This is a technique that has worked well in 
standardizing the detection of influenza in avian samples among 
the E U and the World Organisation for Animal Health reference 
laboratories. Standardizing internal controls used in real-time 
PCR assays can also assist with the problem stated previously of 
PCR inhibitors in samples. Again, there are numerous 'home-
brew' internal controls reported in the literature, but the design 
and use of good appropriate internal controls within a PCR are 
essential if it is to be used with confidence in a diagnostic setting. 
Perhaps the most fundamental challenge to implementing 
molecular diagnostics for clinical use is that of assay design, 
which is essentially which genes to target. This review has already 
described the challenges associated with designing a MRSA-
specific assay, and, indeed, the short synopsis presented is very 
much an abbreviation of the problem. As our knowledge of bac-
teria and their genomes escalates, it becomes clear that the con-
cept of Virulence' genes is outdated and that, owing to genetic 
exchange between microbes, there are many ubiquitous organ-
isms that contain genes once thought to be unique to pathogens. 
Similarly, there are numerous bacterial pathogens that appear to 
carry no real virulence genes, which are indispensable for their 
ability to cause disease [35). This leads to a major challenge in using 
genetic identification for diagnostics; put simply, relying on one 
gene to identify a pathogen within a sample from normal microbial 
flora is becoming less and less reliable for a 
large number of pathogenic bacteria. Again, 
this is perfectly illustrated by the case of 
MRSA, where detection of the mecA gene 
alone is not sufficient to type an organism 
as MRSA; even using two target genes can 
lead to confused diagnosis owing to mul-
tiple bacteria present in a sample containing 
one or more of the target genes. 
A similar problem exists in C. difficile, 
where debate exists on which combination 
of toxin A and B is relevant to consider the 
organism a pathogen. A recent landmark 
publication has suggested that only toxin B is 
essential for human virulence [36]. Similarly, 
epidemiology laboratories also need to dis-
tinguish between classical C. difficile and the 
emerging hypervirulent C. difficile respon-
sible for the mass healthcare fatal outbreaks 
reported. The major difference between 
these is a minor mutation in a gene that reg-
ulates production of toxin B, which is prac-
tically impossible to assess by conventional 
PCR [37]. 
More advanced uses of molecular 
biological technology 
In order for molecular diagnostics to be uti-
lized in a clinical setting with the required 
level of accuracy and reliability, it is clear that more sophisticated 
strategies are required than simply PCR. At the very least, well-
designed and robust multiplex P C R assays that target unique sets 
of genes are required to unequivocally identify a large number of 
pathogenic organisms. Alternatively, strategies, such as real-time 
P C R and melt-curve analysis, can be used to identify pathogens 
where simple genetic mutations render them pathogens compared 
with their less harmful close relatives [38]. This is an extremely 
powerful tool that allows the P C R assay to detect single base pair 
differences in the gene being targeted. It does so by allowing the 
PCR to progress to the end of the reaction, and then measures 
the exact temperature at which the amplified product denatures 
into ssDNA (the melt temperature). This exact temperature will 
vary i f the sequence differs by as little as one nucleotide. Such 
modifications of real-time PCR would allow diagnostic assays to 
circumvent problems such as the one described previously for C. 
difficile, and may also have added benefits during diagnosis, such 
as detection of mutations in target genes, a key feature of note 
during, for example, influenza outbreaks. 
In addition, the adaptation of microrray technology to diag-
nostics would allow full differentiation of a pathogen from a 
nonpathogen. This could, in theory, allow the nucleic acid from 
a sample to be extracted, then hybridized to a glass slide con-
taining D N A fragments complementary to the genes of interest, 
unique to the pathogen being tested for. In theory, this could 
also allow sample type screens, rather than individual tests for 
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each pathogen. For example, a microarray 
slide could be created containing a number 
of unique gene segments for all pathogens 
associated with respiratory disease. This 
would then allow the clinical laboratory 
to process a respiratory sample and then 
hybridize to the slide to allow identifica-
tion of all pathogens present in that sample 
in one quick assay. Another added benefit 
is that such a gene-panning approach could 
also theoretically employ antibiotic resis-
tance genes, so that almost all antibiotic 
resistances present in a sample could be 
ascertained, which is still a major hurdle 
in persuading clinicians to adopt molecu-
lar diagnostics over culture-based isolation 
and characterization of the resulting isolate. 
While this sounds like diagnostic nirvana, 
there are numerous obstacles to such tech-
nology being employed in a clinical setting. 
These include the cost and level of user skill 
required for the technology, and also the 
amount of pathogen D N A required to nuo-
rescently label and then hybridize to the 
slide to produce a detectable signal. This 
can be overcome by PCR-based amplifica-
tion of the D N A in the sample, but this is 
incredibly difficult i f attempting to amplify 
hundreds of gene segments for the type of 
array previously mentioned [17]. 
Sample collection 
Bacterial cell lysis if required 
(vortex/heat/enzyme) 
c 
E 
o 
CO 
DNA/RNA extracted 
Amplification and 
fluorescent labeling 
0 
^ 1 
^ 
^ 
Fluorescent signal detection 
1
— Result reported 
, 3 
^ IT1 k ^ 
Towards an ideal rapid diagnostic 
device: fully automated devices 
In order for rapid diagnostics to be fully 
accepted in clinical and point-of-care set-
tings, the major challenge is automation. 
This would save labor time and, ideally, 
allow multiple samples to be analyzed at 
once. It would reduce the time of exposure 
of technical staff to potentially infectious 
samples and may reduce contamination 
of samples, thus reducing false-positive 
results. Automation should permit greater 
standardization of tests, and systems that are easy to use would 
open the diagnostic process to operation by unskilled staff, 
increasing the number of people able to run diagnostic analyses. 
A portable, automated diagnostic system would be the ideal 
target for development, as this would dramatically increase 
diagnostic flexibility by allowing point-of-care diagnosis and 
diagnostic ability in nonclinical settings [39]. For an automated 
test to be incorporated into routine clinical use, it must be as 
effective as current manual methods, with the same level of 
accuracy, be time- and labor-saving and cost effective. Ideally, 
an automated system would incorporate sample preparation, 
most commonly in the form of nucleic acid extraction, with 
Data transmission 
Treatment undertaken 
Expert Rev. Med. Devices © Future Science Group (2009) 
^ 4 
^ 
^ 
Figure 3. Ultimate molecular diagnostic protocol. A fully automated device 
producing a specific, sensitive and reliable diagnosis in a 30-min time frame. +: Positive 
for pathogen; -: Negative for pathogen; ?: Result unclear. 
some form of real-time P C R or microarray-based detection 
of pathogen D N A involving fluorescent labeling and signal 
detection (FIGURE 3). 
Commercial developers have begun to address some of these 
requirements with regards to automated D N A extraction from 
samples, and two of the devices that have been most extensively 
tested are the MagNA Pure L C (Roche) and the BioRobot® M48 
(Qiagen). When compared with established manual methods, 
these automated procedures were found to be comparable or better 
owing to reduced contamination [40-45]. Costa et al. were also able 
to incorporate an ultraviolet decontamination step into their assay 
in the MagNA Pure L C to further reduce contamination [46]. 
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Table 2. Automated/semi-automated diagnostic systems. 
w^mmmm •mm 
Gen-Probe Inc. 
Neogen Corp. 
Oxiod (ThermoFisher Scientific) 
BAX System Q7 from Du Pont 
Quaiicon Inc. 
Roche Diagnostics 
Idaho Technology 
AccuProbe™ culture 
GENE-TRAK 
GeneQuence® 
BAX® Salmonella Kit 
LightCycler® Foodproof Detection Kit 
Salmonella (also 
Campylobacter in RAPID 
defence system) 
Campylobacter 
Salmonella 
Salmonella 
Salmonella 
Campylobacter 
Salmonella 
Probe hybridization 
Probe hybridization 
Probe hybridization causing a 
colour change detected 
spectrophotometrically 
(automated, 372 samples in ~4 h) 
PCR 
RT-PCR 
PCR 
RAPID® LT Food Security System 
(Salmonella LT) 
RT-PCR using freeze-dried 
reagent pellets 
Pathogen Test Kit 
Real Alert PCR Kits 
Luminex LabMAP™ System 
AnDiatec® Salmonella PCR-ELISA 
Artus Biotech 
Liminex Corp. 
AnDiatec GmbH 
RT: Real time. 
Magnetic D N A extraction methods lend themselves to auto-
mation since they remove the need for liquid-handling steps; the 
DNA, once liberated from the cells in question, is bound to mag-
netic particles and transported between different washing and 
eluting solutions by an automated magnetic arm. These protocols 
often do not require centrifugation or heating steps, which makes 
automation more straightforward. The Enigma F L PCR-Light® 
(Enigma Diagnostics, Wiltshire, UK) incorporates a magnetic-
based D N A extraction process, including a centrifugation step, 
with real-time P C R in a portable diagnostic device designed for 
use by the army. This makes use of lyophilized PCR reagents that 
are stable for storage and provides a diagnostic result in less than 
30 min [39]. Further modifications are currently being made to this 
technology to better tailor it to the clinical point-of-care market. 
Another aspect of molecular diagnostic automation that 
requires attention is the addition of the initial sample prepara-
tion stages to the molecular assay. This, in most cases, will involve 
the lysis of bacterial cells and extraction of their D N A . The effect 
of amplification inhibitors that are copurified with D N A from 
clinical samples has been discussed earlier; however, this is not 
the only challenge for D N A extraction. The lysis of bacterial cells, 
particularly Gram-positive species, is a barrier since it requires 
processes that are potentially difficult to incorporate into an auto-
mated system. The principle methods used to lyse bacterial cells 
include heating, enzyme action and physical disruption, usually 
by beating with glass or porcelain beads. In many cases, manual 
protocols employ more than one method; the QIAamp® mini 
stool kit and GenElute™ kit use both heat and enzyme action, 
while the FastDNA® Soil kit uses physical disruption followed 
by enzyme action. Adding an enzyme reagent to the automated 
process is not as complicated as adding a heating element (may 
Campy/Salmonella 
Campy/Salmonella 
Campy/Salmonella 
Salmonella 
PCR 
PCR 
PCR-ELISA 
need to heat up to 95°C for bacterial cells) or a vortex action suf-
ficiently vigorous to break open cells. However, an enzyme alone 
is not always enough to fully lyse cells, which is why multiple 
lysis methods are used in many manual kits. The nature of clini-
cal samples adds extra difficulty due to the presence of viscous 
or particular substances. Producing a portable device that will 
effectively extract D N A from clinical samples will be a major step 
forward in clinical diagnostics. 
Perhaps the greatest challenge to producing a fully automated 
diagnostic device is the integration of all of the component stages 
into one small footprint machine. Integrating sample preparation 
with D N A extraction, followed by amplification/DNA labeling 
and then readout, are major engineering challenges that require 
a very much interdisciplinarian approach to solve. 
Expert commentary 
In line with the contrasting advances and challenges listed in this 
review, the development of point-of-care rapid diagnostics is an 
area that is a major focus of research sources, yet at the same time, 
very few devices are currently commercially available. Current 
automated devices in use or development are primarily targeted 
toward the food industry or the military; examples are listed in 
TABLE 2. Further development of these devices is required to better 
suit them to mass clinical use. 
Probably the greatest success for rapid diagnostics to date is the 
Cepheid GeneXpert® system, based on the SmartCycler® used 
in many clinical and research laboratories for real-time PCR and 
the various molecular tests developed for the sexually transmit-
ted pathogens Chlamydia trachomatis and Neisseria gonorrhoeae 
(CTNG). The GeneXpert is a fully automated closed system that 
automates sample preparation, D N A amplification and detection. 
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CTNG Cobas Amplicore® 
Abbott LCx® 
Abbott Realtime CTNG 
BD ProbeTec ET® 
Gen-Probe A M P CT® 
Gen-Probe Aptima Combo 2® 
NucliSens® 
There are currently three commercial 
GeneXpert systems available for Enteroviral 
meningitis, Group B Streptococcal'mkctions 
and, most notably and successfully, for 
MRSA detection [47-49]. C T N G tests have 
been developed by a number of different 
companies (TABLE 3) and are now routinely 
used in clinical settings. Indeed, the devel-
opment of chlamydial tests based on nucleic 
acid-amplification technology has been 
considered the most important advance 
for the detection of chlamydial infections 
since cell culture. 
The success of implementation of molec-
ular-based diagnostic tests for C T N G 
should pave the way for more molecular 
diagnostics becoming common place in clinical laboratories, 
particularly when they replace cumbersome and tiresome cul-
ture- or serology-based diagnostics. A fine example of this is the 
recent implementation of the molecular test developed by the 
U K Health Protection Agency for HINlv , or swine flu. After 
being developed and validated by the reference research labora-
tories, the real-time P C R was rolled out to all frontline clinical 
diagnostic laboratories to expedite the fast turn around of swine 
flu diagnosis. This molecular test completely replaced all serol-
ogy- and culture-based techniques. This is a practice that has 
been employed by veterinary avian influenza laboratories for the 
last few years [so]. However, one key point to understand is that 
molecular diagnostics should never be viewed as away to replace 
conventional diagnostics but as a way of supplementing them, 
and may be best considered as a value-added tool to incorporate 
into the diagnostic algorithm. 
Five-year v i e w 
As the amount of research funding for rapid point-of-care diag-
nostics has increased exponentially over the last 24 months, it 
is fair to hope that so too will the number of devices reaching 
the clinical market, particularly with funding schemes such as 
the E U FP7 funding initiatives, technology strategy board health 
technologies initiative and the N I H R Ideas4innovation small 
business research initiative. These funding schemes have seen 
several million pounds invested in small and medium enterprises 
and academic partnership research in an attempt to bring expert 
knowledge of pathogens and pathogen genomics, with expertise of 
developing and constructing state-of-the-art engineering solutions 
to rapid diagnostic devices. 
In the next 5 years, we should see a wider choice of robust point-
of-care devices made available to the medical profession. Devices 
such as the Enigma FL are now being further developed to create 
a small footprint device to perform fully automated sample extrac-
tion and real time P C R that can be used to diagnose healthcare-
associated infections, C T N G , intestinal infectious diseases and 
influenza. The Enigma device is possibly the most advanced in the 
U K with respect to fully integrating all components of infectious 
disease diagnosis into a fully automated device. 
Table 3. Various molecular diagnostic devices available for Chlamydia 
trachomatis and Neisseria gonorrhoeae testing. 
mm 
Roche 
Abbott diagnostics 
Abbott diagnostics 
Becton-Dickinson 
Gen-Probe 
Gen-Probe 
Organon Teknika 
CTNG: Chlamydia trachomatis and Neisseria gonorrhoeae; LCR: Ligase chain reaction; NASBA: Nucleic acid 
sequence-based amplification; TMA: Transcription-mediated amplification. 
PCR/ Hybridization 
LCR 
Real-time PCR 
Strand displacement amplification 
Transcription-mediated amplification 
Second-generation T M A 
NASBA 
The last two E U FP7 calls for research funding have heavily 
targeted the development of diagnostics, and this also should 
bear fruit in the next few years. Among several projects funded 
to speed up the diagnosis and detection of influenza in this ini-
tiative are the Enigma device for influenza detection based on 
real-time PCR, and the PortFastFlu project, which has garnered 
a lot of press interest worldwide owing to its design, incorporating 
sample preparation and amplification using small microfluidic 
microchips, and real-time microarray to allow detection and virus 
typing in one small, briefcase-sized machine. The technology 
is based on the HybLive technology developed by the French 
company Genewave, a spin-off small-to-medium enterprise from 
Ecole Polytechnique in Paris, as well as microfluidic expertise 
developed by Gaiker and Ikerlan of Spain. 
While much of this review has focused on molecular-based 
detection of infectious agents, it is important to also note that 
many companies are aiming to speed up more classical methods 
of diagnosis, allowing them to be performed cheaper and far faster 
than they conventionally do. One such example is the recently 
reported Universal Sensors project. This uses biosensor technology 
to make the classical serological/antigen-detection ELISA tests 
faster, cheaper and much more sensitive, potentially as sensitive 
as PCR. The benefits are that the reagents and tests are greatly 
reduced in cost compared with molecular methods, and the actual 
test platform is highly portable, potentially a handheld device. 
In brief, as more companies and academic researchers switch 
attention to the need for point-of-care rapid diagnostics, the next 
5 years should see a real shift in the way infectious diseases are diag-
nosed and managed. The emphasis on general practitioner sampling 
and large throughput of samples by the clinical laboratory will begin 
to be heavily supplemented by the use of such machines. This will 
allow diagnosis of infectious diseases to occur faster, allow more 
efficient treatment and lessen the burden on already overloaded 
clinical laboratories. It will also alleviate the pressure on clinical 
microbiologists created by policies such as routine testing of in-
patients for MRSA, and screening for C. difficile. The recent occur-
rence of the swine flu pandemic may also create the opportunity 
that rapid point-of-care-diagnostics has been waiting for to show 
their real value and reliability during an infectious disease crisis. 
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Key issues 
Infectious disease is a major health concern to the 
global population. 
Rapid diagnosis of infectious disease is a key strategy in 
lessening their burden. 
Molecular techniques based on pathogen genetics are key in 
developing rapid diagnostics. 
Key challenges are integrating complex procedures of 
sample preparation and assay into a single 
automated machine. 
Current and future research should see a rise in the number 
of reliable and robust point-of-care rapid diagnostic devices 
available to the healthcare profession. 
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